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A B S T R A C T
The objective of the present study was to exhibit the enhanced water-solubility and in vivo
oral absorption when febuxostat (FXT) became the salt formation of choline. The forma-
tion of the choline salt of febuxostat was confirmed by X-ray powder diffraction, infrared
spectroscopy analysis and differential scanning calorimetry. The direct filling method was
used to develop a capsule formulation. Cellactose 80 was used as the filler due to its good
fluidity, while cross-linked polyvinylpyrrolidone (PVPP) and magnesium stearate (MS) were
used as the disintegrant and lubricant, respectively. Then the in vitro release of the formu-
lation was carried out in five different dissolution media including HCl solution (pH 1.2),
acetate buffer (pH 4.5), phosphate buffer (pH 6.8 and pH 7.2) and water. Evident improve-
ment of release for choline febuxostat (CXT) was presented in water while the dissolution
degree was decreased for CXT in the medium of phosphate buffer (pH 6.8) in comparison
with FXT. Furthermore, the pharmacokinetics of CXT was studied in rats using UPLC-MS/
MS compared with FXT. The data acquired illustrated that AUC0-24h of CXT and FXT were
22,245.96 ± 7342.92 μg·h/l and 12,249.70 ± 2024.04 μg·h/l, respectively.The relative bioavailability
of CXT to FXT was about 181.6% and the P value of AUC0-24h was less than 0.05. It showed
significant difference between the two drugs after oral administration. In conclusion, the
water-solubility and oral bioavailability were both improved remarkably for the choline salt
of febuxostat and choline salinization was proved an effective way to increase the in vivo
absorption for FXT.
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Febuxostat (FXT) is a novel drug which is developed for the
treatment of gout and hyperuricemia. As an inhibitor of xan-
thine oxidase, it provides a selective and potent property
compared with allopurinol [1]. FXT acquired admission from
the Food and Drug Administration (FDA) in 2009. It was the first
new drug the FDA approved in 40 years, which was used for
lowering the level of serum uric acid (sUA) in vivo [2]. In recent
years, FXT has acquired extensive attractions owing to its good
therapeutic effect.
FXT is a weak acid (PKa 3.42) [3] which is practically in-
soluble in water and the solubility was about 12.9 μg/ml in water
at 37 °C [4]. The bioavailability of FXT is approximately 80%
and the half life is about 5–8 h [5]. FXT is classified as a
Biopharmaceutics Classification System (BCS) II drug due to
its low solubility and high permeability [6]. In general, the
primary problem of formulation for BCS II drugs is how to
improve the dissolution.Water solubility is the main factor that
influences the bioavailability of this kind of drug [7]. Al-
though FXT shows good pharmaceutical behavior, the
improvement of aqueous solubility would be conducive to the
absorption process [8]. Poor aqueous solubility could be im-
proved inmany ways, such as nanosuspension, solid dispersion,
co-crystals, hydrates and salts [9–11]. In the past few decades,
the water-soluble derivative has become widely used for the
development of new drugs, especially for the salt formation.
The physicochemical property of salt was much different from
the parent drug [12]. In general, solubility would be improved
without destroying the inherent nature of active pharmaceu-
tical ingredient (API) [13] when poorly water-soluble drugs were
turned into pharmaceutical salts [14–16] and the in vivo
bioavailability was likely to be enhanced a lot [17–20]. There-
fore, pharmaceutical salts seem to be a simple and rugged
strategy being considered to change the solubility or other prop-
erties for FXT.
The purpose of the present study was to provide a novel
way to improve the aqueous solubility and in vivo bioavailability
of FXT. There were scarcely any reports about the salt forma-
tion of FXT which introduced its dissolution behavior and
bioavailability in details so far. In this assay, the choline salt
of febuxostat (Fig. 1) which was synthesized by FXT and choline
chloride was investigated.The solubility of choline febuxostat
(CXT) was determined in water at 37 °C (approximately
30 mg/ml) and it proved excellent in water solubility compared
with FXT. First, it was necessary to evaluate the dissolution be-
havior of CXT in media at different pH levels. Usually, a
satisfactory release in vitro of a drug indicates a good in vivo
absorption [21–23]. Second, the relative bioavailability of the
salt was studied in rats in comparison with FXT and a sensi-
tive UPLC-MS/MS method was used for the determination of
drug in rat plasma.
2. Materials and methods
2.1. Chemicals and reagents
Febuxostat (FXT, purity 99.9%) and choline febuxostat (CXT,
purity 99%) were obtained from Kangya Pharmaceuticals Co.,
Ltd. Choline chloride was purchased from Bangcheng Chemi-
cal (Shanghai, China). Microcrystalline cellulose (PH 102) was
obtained from Asahi Kasei Corporation (Japan). Lactose and
Cellactose® 80 were provided by Meggle Excipients & Tech-
nology (Germany). Carboxymethyl starch sodium (CMS-Na),
crospovidone, low-hydroxypropyl cellulose (L-HPC) and mag-
nesium stearate (MS) were kindly gifted by Anhui Sunhere
Pharmaceutical Excipients Co., Ltd (Anhui, China). Glimepiride
(internal standard, IS) was obtained from Conquer Pharma-
ceuticals Co., Ltd (Chongqing, China). HPLC-grademethanol and
acetonitrile were purchased from Fisher Scientific (Pitts-
burgh, PA). HPLC-grade formic acid was obtained from Dikma
Technologies (Richmond Hill, NY, USA). High-purity water was
used through the study. All the other chemicals were of ana-
lytical grade.
2.2. Chromatographic conditions and mass
spectrometry detection
The analytes were eluted on a Phenomenex Kinetex XB-C18
column (50 mm × 2.1 mm, 2.6 μm) at 40 °C with a flow rate of
0.2 ml/min. A mobile phase of acetonitrile and water (contain-
ing 0.2% formic acid) was used and the gradient condition was
shown in Table 1. The injection volume was 5 μl.
For MS detection, a triple–quadruple mass spectrometer
(waters Corp, Milford, MA, USA) was operated in the positive
electrospray ionization (ESI+) mode with the multiple reac-
tion monitoring (MRM) mode for analysis. The source
temperature and desolvation temperature of the instrument
were employed at 150 °C and 350 °C, respectively. The capil-
lary voltage was 2.40 kV and the cone voltage was 45 V for
febuxostat and 30 V for IS. Moreover, the desolvation gas ve-
locity was 650 l/h and the collision energy (CE) was 20 V. The
Fig. 1 – Molecular structure of choline febuxostat (CXT).
Table 1 – UPLC gradient eluting condition for detection
of FXT and CXT.
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optimized transitions were m/z 317.2 → 261.1 and m/z 491.2
→ 126.2 for the analyte and IS, respectively. MassLynx 4.1 soft-
ware (Waters Corp., USA) was employed for data processing.
2.3. Characterization
2.3.1. X-ray powder diffraction (PXRD) analysis
FXT, CXT, choline chloride and the physical mixture of FXT and
choline chloride were analyzed on X-ray diffractometer (D/
Max-2400, Rigaku Corporation, Japan). The instrument was
operated at 40 KV and 30 mA.The samples were scanned from
5° to 50° (2θ) at a scan rate of 0.03°/min.
2.3.2. Fourier infrared spectrometry (FT-IR)
Potassium bromide pellet technique was used for the deter-
mination of the samples on infrared spectrometer (EQUINOX
55, Bruker Corporation, Germany), including FXT, CXT, choline
chloride and the physical mixture of FXT and choline chlo-
ride. The wave number ranged from 400 to 4000 cm−1.
2.3.3. Differential scanning calorimetry (DSC)
The variation of melting point and crystal form of samples were
demonstrated on a DSC instrument (STARe, Mettler Toledo Cor-
poration, Switzerland). FXT, CXT, choline chloride and the
physical mixture of FXT and choline chloride were weighed
(2–5 mg) and heated in aluminum pans, respectively.The scan-
ning rate was 10 °C/min and the temperature ranged from 20 °C
to 300 °C. The flow rate of nitrogen gas was set at 40 ml/min.
2.4. Preparation of capsules
The direct filling method was applied for the capsule prepa-
ration, with which the powders of bulk drug and various
excipients were blended uniformly and then loaded into cap-
sules without granulation. The crude of CXT and FXT were
passed through 100 mesh and the excipients were all passed
through 80 mesh. The designed five formulations were listed
in Table 2. First, the fixed amount of CXT was blended with
MS uniformly, and then the mixture was blended with the
disintegrant and diluent thoroughly at a fixed proportion. Finally,
300 mg of the compound (40 mg of FXT equivalently) was trans-
ferred into 0# gelatin capsule. FXT capsules were prepared with
the optimized formulation and craft as comparison.
2.5. Dissolution tests
The capsules of CXT and FXT were both employed for the ex-
periment of drug release in vitro. Five different dissolutionmedia
were used to investigate the behavior of the drugs, including
HCl solution (pH 1.2), acetate buffer (pH 4.5), phosphate buffer
(pH 6.8 and pH 7.2) and purified water. These media were all
prepared according to the United States Pharmacopeia (USP).
The dissolution tests were performed at 37 °C in 900 ml of cor-
responding medium by using the paddle method at 50 r/min
according to the USP.Tenmilliliters of the solution was removed
out at the time of 5, 10, 15, 20, 30, 45 and 60 min. Then 10 ml
of blank medium at 37 °C was injected into the dissolution
system rapidly. Subsequently, the acquired sample was fil-
tered through 0.45 μm filter and then diluted by corresponding
medium to obtain appropriate absorbance, which was deter-
mined by UV detection (UV-1801, Ruili Analytical instrument,
Beijing) at 316 nm.
2.6. Pharmacokinetic study
Ten Sprague–Dawley rats (male, 220–250 g), which were pro-
vided by the Animal Center in Shenyang Pharmaceutical
University, were divided into two groups, A and B, randomly.
The guidelines of the Care and Use of Laboratory Animals were
used throughout the experiment and the Committee of Ethics
of Animal Experimentation of Shenyang Pharmaceutical Uni-
versity had given the permission. No diet was permitted for
12 hours before the experiment. The capsule content of FXT
and CXT were poured out to prepare the corresponding solu-
tion before administration. Group A was administered CXT
aqueous solution orally equivalent to 5 mg/kg of FXT while
group B was administered FXT suspended in 0.5% CMC-Na at
a constant dose. Blood samples (0.3 ml) were collected within
24 h from eye sockets and added into heparinized tubes at 0.083,
0.167, 0.25, 0.333, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12 and 24 h after oral
administration. The samples were centrifuged at 13,000 rpm
for 10 min instantly and the separated plasma (100 μl) was
stored at −20 °C for analysis.
2.7. Sample preparation
First, 25 μl of mobile phase and 50 μl of IS solution (100 ng/ml)
were added into 25 μl of plasma sample and vortex-mixed for
1 min. Then 150 μl of acetonitrile was added into the mixture
and vortexed for 1 min again. Finally, the sample was centri-
fuged at 13,000 rpm for 10 min and 5 μl of the supernatant was
injected into UPLC-MS/MS for analysis.
3. Results and discussion
3.1. Characterization
3.1.1. X-ray powder diffraction (PXRD) analysis
Fig. 2 presented the PXRD patterns of various powders at 2θ
values between 5° and 50°. Obvious peaks were found in spectra
of choline chloride and FXT (Fig. 2C and D), while there were
scarcely any peaks within the pattern of CXT (Fig. 2A), which
indicated that an amorphous state had been formed. Fig. 2B
showed that the peaks of choline chloride were not particu-
larly evident.The reason may be the nonuniformity in blending
process due to the deliquescence property of choline chloride.
Table 2 – Design of formulations for CXT capsules (n = 5).
Ingredients (mg) F1 F2 F3 F4 F5
CXT 53 mg (equivalent to 40 mg of febuxostat)
Lactose 236.5 0 0 0 0
MCC (PH 102) 0 236.5 0 0 0
Cellactose 80 0 0 236.5 236.5 236.5
Crospovidone 9 9 9 0 0
CMS-Na 0 0 0 9 0
L-HPC 0 0 0 0 9
MS 1.5 1.5 1.5 1.5 1.5
Total 300 300 300 300 300
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3.1.2. Fourier infrared spectrometry (FT-IR)
As shown in Fig. 3, some typical functional group had changed
in the structure of CXT compared with FXT. FXT had free func-
tional group of COOH at the wave number of 1681 cm−1, which
still existed in the physical mixture. However, peaks near the
wave number of 1681 cm−1 were not found in Fig. 3C, indicat-
ing that the structure of FXT was changed and the salt was
formed.
3.1.3. Differential scanning calorimetry (DSC)
The DSC thermograms of samples were exhibited in Fig. 4. A
sharp endothermic peak (about 212 °C) was displayed in Fig. 4D,
which was consistent with the melting point of FXT.There was
no obvious characteristic peak in choline chloride (Fig. 4C)
during the heating process and the peaks in themixture (Fig. 4B)
contained the response of FXT and choline chloride. In addi-
tion, an exothermic peak (about 175 °C) was observed in Fig. 4A,
which indicated that the salt was transformed from an amor-
phous state to a stable crystal state. The result was in
accordance to PXRD.The two endothermic peaks at 243 °C and
285 °C suggested that the stable crystal form may contain two
different kinds of crystal types.
3.2. Preparation of CXT capsules
Different kinds of fillers and disintegrants were investigated
by evaluating the fluidity of content and dissolution behavior
of capsules.When MCC or lactose was chosen as the filler, the
content fluidity was not better than Cellactose 80. Poor fluid-
ity would induce to content nonuniformity of capsules. Thus,
Cellactose 80 was suitable for the preparation of CXT cap-
sules. The dissolution tests were carried out to investigate the
behaviors of three kinds of disintegrants in water. Results
showed that capsules exhibited superior dissolution behav-
ior when crospovidone was employed as the disintegrant.Thus,
the optimized formulation was F3.
3.3. In vitro release
By comparing the dissolution behavior of CXT with that of FXT
in different media, it was noticed that FXT and CXT were both
barely dissolved in the media of pH 1.2 and pH 4.5. However,
FXT showed a much slower dissolution rate in water com-
pared with CXT (Fig. 5E). In addition, CXT had a similar
performance comparing with FXT in the medium of pH 7.2,
but the release degree was further decreased in the medium
of pH 6.8.The dissolution curves of the formulations were pre-
sented in Fig. 5.
To summarize, it showed significant difference between FXT
and CXT in water and the phosphate buffer (pH 6.8).The chemi-
cal property and dissolution behavior were both changed for
the choline salt of febuxostat and this phenomenon was
Fig. 2 – X-ray diffraction patterns of: (A) CXT, (B) the
physical mixture of FXT and choline chloride, (C) choline
chloride and (D) FXT.
Fig. 3 – FT-IR spectra of: (A) the physical mixture of FXT and
choline chloride, (B) choline chloride, (C) CXT and (D) FXT.
Fig. 4 – DSC thermograms of: (A) CXT, (B) the physical
mixture of FXT and choline chloride, (C) choline chloride
and (D) FXT.
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attributed to the variation of structure and pH sensitivity of
the drug.
3.4. In vivo pharmacokinetics
The in vivo pharmacokinetic parameters were demonstrated
in Table 3. The results showed that Cmax of CXT was
16,582.66 ± 19,053.53 μg/l, while Cmax of FXT was only
4265.80 ± 894.69 μg/l. However, t1/2 was 4.21 ± 1.16 h for CXT,
which was considered the same with FXT (6.14 ± 3.29 h) gen-
erally. Additionally, it showed significant difference between
the two formulations of AUC0-24h (22,245.96 ± 7342.92 μg·h/l for
CXT and 12,249.70 ± 2024.04 μg·h/l for FXT), for which the level
of significance was P = 0.04 < 0.05. The relative bioavailability
was approximately 181.6%. Fig. 6 provided the comparison of
AUC between CXT and FXT.
As a matter of fact, the in vivo absorption of the choline salt
was improved dramatically compared with FXT although it
showed a decreased dissolution degree in the phosphate buffer
(pH 6.8) of the release test. The reasons were illustrated from
several aspects. First, it was a complicated process for an oral
Fig. 5 – The dissolution curves of the two formulations in: (A) HCl solution (pH 1.2), (B) acetate buffer (pH 4.5), (C) phosphate
buffer (pH 6.8), (D) phosphate buffer (pH 7.2) and (E) purified water.
Table 3 – Pharmacokinetic parameters of CXT and FXT
in rats and the corresponding P values.
Parameters CXT FXT P
value
Cmax (μg/l) 16,582.66 ± 19,053.53 4265.80 ± 894.69 0.11
t1/2 (h) 4.21 ± 1.16 6.14 ± 3.29 0.14
CL (l/h/kg) 0.21 ± 0.07 0.33 ± 0.09 -
AUC0–24 h(μg·h/l) 23,303.45 ± 9469.24 12,249.70 ± 2024.04 0.04
AUC0–∞ (μg·h/l) 22,245.96 ± 7342.92 16,429.90 ± 5861.43 0.04
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drug when it entered gastrointestinal tract until absorption.
The mechanism of passive diffusion was applied to most drugs
during their absorption process, which was concerned with the
molecular size, nature of the charge and hydrophilic/lipophilic
property. Second, water-solubility was the key factor that in-
fluenced the bioavailability in vivo. Above all, an excellent
dissolution behavior in water was presented for CXT while FXT
behaved worse.The comprehensive effects resulted in the above
result.
In this paper, it was notable that the oral bioavailability was
significantly enhanced when a poorly water-soluble drug was
turned into its salt formation. The choline salt of febuxostat
was a novel derivative which had a superior absorption and
the relevant preparations could be developed in the future.
4. Conclusion
To sum up, FXT became an aqueous compound through the
way of choline salinization and the in vivo bioavailability was
improved with a 180-fold enhancement.Thus, it proved an ef-
fective way to increase the drug absorption by salt conversion,
especially for those water-insoluble drugs. The results ac-
quired are finally beneficial for individuals that have been
working on FXT or other BCS II drugs.
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